Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19772422 | 1.00 | NR1I2 (0.35) | NR1I2NPC1RAB9ADNM1MEN1 | |
| SCHEMBL23172210 | 0.98 | NR1I2 (0.36) | NR1I2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18948523 | 0.98 | NR1I2 (0.36) | NR1I2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20122136 | 0.98 | NR1I2 (0.36) | NR1I2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26771643 | 0.88 | NR1I2 (0.36) | NR1I2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25718332 | 0.84 | IDO1 (0.32) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL18885072 | 0.83 | NR1I2 (0.35) | NR1I2DNM1KMT2AALDH1A1 | |
| SCHEMBL20273118 | 0.83 | NPC1 (0.35) | NPC1RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL23172597 | 0.81 | NR1I2 (0.36) | NR1I2LMNA | |
| SCHEMBL23172413 | 0.81 | NR1I2 (0.36) | NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | NR1I2 1569/4885NPC1 3704/4885RAB9A 2450/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | NR1I2 1178/4885NPC1 928/4885RAB9A 21/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | NR1I2 1569/4885NPC1 3704/4885RAB9A 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.